Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Down – Time to Sell?

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) gapped down prior to trading on Wednesday . The stock had previously closed at $13.97, but opened at $13.58. Bayer Aktiengesellschaft shares last traded at $13.61, with a volume of 43,051 shares traded.

Analyst Ratings Changes

BAYRY has been the topic of several research reports. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd. Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. Finally, DZ Bank raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Trading Down 0.2%

The stock has a 50-day simple moving average of $11.77 and a 200 day simple moving average of $11.88. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06. The company has a market cap of $53.45 billion, a price-to-earnings ratio of -21.25, a PEG ratio of 4.37 and a beta of 0.55.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.15. Bayer Aktiengesellschaft had a positive return on equity of 17.61% and a negative net margin of 4.75%.The firm had revenue of $15.73 billion during the quarter, compared to analysts’ expectations of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, equities research analysts predict that Bayer Aktiengesellschaft will post 1.25 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.